Azitra (AZTR) Depreciation and Depletion (2022 - 2026)
Azitra (AZTR) posted Depreciation and Depletion of $33081.0 for Q1 2026, up 5.89% on a QoQ basis from $31240.0 in Q4 2025, and up 6.83% year-over-year from $30967.0 in Q1 2025.
Azitra (AZTR) Depreciation and Depletion (2022 - 2026) Analysis & Trends
Azitra's Depreciation and Depletion history runs 5 years deep, the most recent figure standing at $33081.0 for Q1 2026.
- Quarterly Depreciation and Depletion rose 6.83% year-over-year to $33081.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126471.0 (up 4.47% YoY) and the FY2025 annual result came in at $124357.0, up 3.61% from the prior year.
- Depreciation and Depletion was $33081.0 for Q1 2026 at Azitra, up from $31240.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $33081.0 in Q1 2026 and bottomed at $29935.0 in Q1 2024.
- A 5-year average of $30644.8 and a median of $30519.0 in 2022 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2024 — Depreciation and Depletion retreated 3.05% — and 2026, when it advanced 6.83%.
- Azitra's Depreciation and Depletion stood at $30486.0 in 2022, then fell by 1.56% to $30010.0 in 2023, then climbed by 0.46% to $30149.0 in 2024, then increased by 3.62% to $31240.0 in 2025, then advanced by 5.89% to $33081.0 in 2026.
- Business Quant data shows AZTR's Depreciation and Depletion at $33081.0 in Q1 2026, $31240.0 in Q4 2025, and $31041.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 39.39 Mn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 2.20 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 33,081.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,081.00 |
| Mar 31, 2026 | 33,081.00 |
| Dec 31, 2025 | 31,240.00 |
| Dec 31, 2025 | 31,240.00 |
| Sep 30, 2025 | 31,041.00 |
| Sep 30, 2025 | 31,041.00 |
| Jun 30, 2025 | 31,109.00 |
| Jun 30, 2025 | 31,109.00 |
| Mar 31, 2025 | 30,967.00 |
| Mar 31, 2025 | 30,967.00 |
| Dec 31, 2024 | 30,149.00 |
| Dec 31, 2024 | 30,149.00 |
| Sep 30, 2024 | 30,007.00 |
| Sep 30, 2024 | 30,007.00 |
| Jun 30, 2024 | 29,935.00 |
| Jun 30, 2024 | 29,935.00 |
| Mar 31, 2024 | 29,935.00 |
| Mar 31, 2024 | 29,935.00 |
| Dec 31, 2023 | 30,010.00 |
| Dec 31, 2023 | 30,010.00 |